Verrica Pharmaceuticals is a dermatology-focused therapeutics company that develops and commercializes clinician-administered medications for skin diseases, including cancers and viral infections. The company's core commercial product is YCANTH, a proprietary cantharidin-based topical treatment delivered via a precision applicator for molluscum contagiosum and common warts, which generates revenue through direct product sales to dermatologists, pediatricians, and primary care providers via specialized distribution and reimbursement arrangements. The company also owns a pipeline asset, VP-315, an oncolytic peptide therapy licensed for dermatological oncology applications such as basal cell carcinoma, and derives additional revenue through milestone payments and royalties from collaborations with international partners, particularly Torii Pharmaceutical for geographic expansion and Lytix BioPharma for the licensed therapy.